Adeno-Hydroxo B12

Drug overview for ADENO-HYDROXO B12 (hydroxocobalamin acetate/cobamamide):

Generic name: hydroxocobalamin acetate/cobamamide
Drug class: Cobalamines
Therapeutic class: Electrolyte Balance-Nutritional Products

Vitamin B12, a cobalt-containing B complex vitamin, is commercially available as cyanocobalamin and hydroxocobalamin, which are synthetic forms of vitamin B12. Hydroxocobalamin (Cyanokit(R)) is an antidote for cyanide poisoning.

No enhanced Uses information available for this drug.

DRUG IMAGES

No Image Available

The following indications for ADENO-HYDROXO B12 (hydroxocobalamin acetate/cobamamide) have been approved by the FDA:

Indications:
None.

Professional Synonyms:
None.

The following dosing information is available for ADENO-HYDROXO B12 (hydroxocobalamin acetate/cobamamide):

Dosing
Administration
Dosing Information
Generic

For the treatment of pernicious anemia, the usual initial IM or subcutaneous dosage of cyanocobalamin is 100 mcg daily for 6-7 days. If clinical manifestations have improved and a reticulocyte response is observed, cyanocobalamin can then be administered in a dosage of 100 mcg every other day for 7 doses and then 100 mcg every 3-4 days for 2-3 weeks. Once hematologic values have returned to normal, cyanocobalamin can be administered IM or subcutaneously in a dosage of 100 mcg once monthly for life.

Folic acid should be used concomitantly if necessary.

For the treatment of vitamin B12 deficiency in adults, the usual IM dosage of hydroxocobalamin is 30 mcg daily for 5-10 days. Once clinical symptoms have subsided and the blood components have returned to normal, monthly IM maintenance doses of 100-200 mcg appear to be sufficient to maintain a normoblastic bone marrow. For the treatment of vitamin B12 deficiency in children, the usual total IM dose of hydroxocobalamin is 1-5 mcg over 2 or more weeks, given in single doses of 100 mcg.

For maintenance, the IM or subcutaneous pediatric dosage is at least 60 mcg per month; however, smaller doses may often suffice for deficiency states not caused by pernicious anemia.

The commercially available cyanocobalamin metered-dose pump delivers 0.1 mL of solution containing 500 mcg of the drug per actuation. The recommended initial dosage of cyanocobalamin nasal spray is 500 mcg (one actuation) administered intranasally once weekly.

The dosage may need to be increased in patients who experience a decline in serum vitamin B12 concentrations after 1 month of therapy with this preparation. Therapy with a parenteral vitamin B12 preparation may be necessary in patients who do not achieve a satisfactory response to intranasal cyanocobalamin.

Cyanocobalamin is administered by IM or deep subcutaneous injection. Cyanocobalamin also is administered orally and intranasally. Hydroxocobalamin is administered by IM injection or IV infusion. Oral therapy with vitamin B12 preparations is markedly inferior to parenteral therapy and should be used only for the treatment of dietary vitamin B12 deficiency in patients with normal GI absorption.

No dosing information available.

No generic dosing information available.

Contraindication List
Leber's hereditary optic atrophy

Moderate List
Atrophic gastritis
Hypokalemia

More Frequent	Less Frequent
None.	Diarrhea Pruritus of skin

Rare/Very Rare
None.

The following precautions are available for ADENO-HYDROXO B12 (hydroxocobalamin acetate/cobamamide):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

Adequate and well-controlled studies have not been conducted in pregnant women. However, vitamin B12 requirements are increased in pregnant women. Parenteral preparations should be used during pregnancy only when the potential benefits justify the potential risks to the fetus.

Vitamin B12 is distributed into human milk. Vitamin B12 requirements are increased in lactating women. Hydroxocobalamin may be administered to lactating women with suspected or known cyanocobalamin poisoning. There is no data available to determine when breastfeeding may be restarted following administration of IV hydroxocobalamin.

No enhanced Geriatric Use information available for this drug.